TGF-β (transforming growth factor-β) signals through serine/threonine kinase receptors and intracellular Smad transcription factors. An important regulatory step involves specific ubiquitination by Smurfs (Smadubiquitin regulatory factors), members of the HECT (homologous to E6-associated protein C-terminus) ubiquitin ligase family, which mediate the proteasomal degradation of Smads and/or receptors. Recently, we have defined a novel interaction between Smads and UCH37 (ubiquitin C-terminal hydrolase 37), a DUB (de-ubiquitinating enzyme) that could potentially counteract Smurf-mediated ubiquitination. We have demonstrated specific interactions between UCH37 and inhibitory Smad7, as well as weaker associations with Smad2 and Smad3. Importantly, Smad7 can act as an adaptor able to recruit UCH37 to the type I TGF-β receptor. Consequently, UCH37 dramatically up-regulates TGF-β-dependent gene expression by deubiquitinating and stabilizing the type I TGF-β receptor. Our findings suggest that competing effects of ubiquitin ligases and DUBs in complex with Smad7 can serve to fine-tune responses to TGF-βs under various physiological and pathological conditions. Studies are currently under way using activity-based HA (haemagglutinin)-tagged ubiquitin probes to identify the full spectrum of DUBs that impact on Smad/TGF-β signalling activity.
Introduction
TGF-β (transforming growth factor-β) is a multifunctional cytokine that is implicated in a broad range of human diseases. For example, aberrant TGF-β signalling can cause fibrosis, cancer, congestive heart failure, chronic obstructive pulmonary disease, liver cirrhosis, kidney disease and cataracts. Understanding the molecular and cellular mechanisms by which TGF-β signals from the cell surface through the cytoplasm to the nucleus is of paramount importance if this pathway is to represent a useful therapeutic target. Following major scientific breakthroughs in the past decade, it is now known that TGF-β signals through cell-surface serine/threonine kinase receptors that phosphorylate R-Smad (receptorregulated Smad) transcription factors in the cytoplasm to effect specific modulation of gene expression [1] . Upon activation, the TGF-β pathway is rapidly 'switched-off' by the I-Smads (inhibitory Smads), Smad6 and Smad7.
Smads and the Smurf (Smad-ubiquitin regulatory factor) ubiquitin ligases
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E6-associated protein C-terminus) family ubiquitin ligases known as Smurfs have been shown to bind R-Smads, and have been implicated in their specific ubiquitination [3] . Interestingly, Smurfs also bind to I-Smads. Following prolonged treatment of cells with TGF-β, the Smad7-Smurf complex forms, exits the nucleus and binds to the activated TGF-β receptor complex (Figure 1 ). Smurf then ubiquitinates the receptor, causing its rapid proteosomal degradation [4] .
Emerging functional roles for DUBs (de-ubiquitinating enzymes)
Ubiquitination of specific target substrates can be opposed by the action of DUBs, which mediate the removal and processing of ubiquitin. These enzymes are likely to be as functionally important as their ubiquitin ligase counterparts, and there are emerging roles for DUBs in cell growth, oncogenesis, development, memory and transcriptional regulation. A recent key review in the field highlights the significance of DUBs in normal cellular function [5] . Well-characterized examples include the human DUB known as HAUSP (herpesvirus-associated ubiquitin-specific protease)/USP7 (ubiquitin-specific protease 7), which can specifically de-ubiquitinate and stabilize the p53 tumour suppressor protein [6] . BAP1 [BRCA1 (breast-cancer susceptibility gene 1)-associated protein 1] is also a DUB that forms a complex with BRCA1 [7] . A number of DUBs, in particular UCH-L1 (where UCH is ubiquitin C-terminal hydrolase), have also been shown to be dysregulated in malignant human cells using an elegant activity-based ubiquitin-specific protease profiling approach [8] . TGF-β binds to the constitutively active type II TGF-β receptor kinase that trans-phosphorylates the type I receptor in the GS (glycine/serine-rich) domain on specific serine/threonine residues. Activated type I receptor kinase then phosphorylates R-Smads, which subsequently recruit Smad4. The activated R-Smad-Smad4 complex then translocates to the nucleus where it regulates specific gene expression. Smad7 is an example of a TGF-β-induced gene. Following prolonged treatment with TGF-β, Smad7 interacts with Smurf1 or Smurf2 and is exported from the nucleus to interact with cell-surface TGF-β receptor complexes. Thus Smad7 acts as an adaptor that recruits the ubiquitin ligase Smurf 1/2 to the TGF-β receptor and causes its rapid proteosomal degradation. UCH37 can bind concurrently to Smad7 and antagonize the action of Smurf 1/2 by specifically de-ubiquitinating the TGF-β type I receptor (TGFβRI), causing rescue from proteosomal degradation.
The DUB UCH37 interacts with Smads and regulates TGF-β signalling
Recently, we have identified a completely novel interaction between inhibitory Smad7 and a ubiquitin C-terminal hydrolase known as UCH37 [9] . We have shown that Smad7 acts as an adaptor that recruits UCH37 to the type I TGF-β receptor and reverses Smurf-mediated ubiquitination (Figure 1) . In addition, we found that RNA interference-mediated knockdown of UCH37 abolished TGF-β-dependent transcriptional responses. UCH37 was first identified as a component of the 26 S proteasome [10] . Proteasome-associated UCH37 removes ubiquitin from the distal end of the Lys 48 -linked polyubiquitin, and it is thought to antagonize the degradation of ubiquitinated substrates by facilitating their release from the proteasome. To our knowledge, our work provides the first report of a biological role for UCH37 that is distinct from its action at the proteasome, although the presence of a separate non-proteosomal pool of UCH37 has been known for some time (R.E. Cohen, personal communication).
Activity-based probes to identify novel DUBs bound to Smads and TGF-β receptors
We cannot exclude the possibility that other DUBs might also influence specific components of the Smad/TGF-β signalling system. Indeed, the human genome encodes over 70 predicted members of this family. Most of the DUBs are cysteine proteases and have been divided into five main subgroups: the UBPs (ubiquitin-specific processing proteases), the UCHs, the OTU (ovarian tumour) domain-containing DUBs, the Josephin domain DUBs and the non-cysteine protease JAMM (JAB1/MPN) metalloenzymes. Interestingly, a JAMM family member known as AMSH [associated molecule with the SH3 (Src homology 3) domain of STAM (signal-transducing adaptor molecule)] regulates TGF-β signalling activity [11] . Many ubiquitin ligases, other than Smurf1 and Smurf2, have also been shown to interact with specific components of the Smad/TGF-β system including ROC1 (RING of cullins 1)/SCF (Skp1/cullin/F-box) [12] , JAB1 [13] , Arkadia [14] and CHIP [C-terminus of Hsc70 (heat-shock cognate 70)-interacting protein] [15] . The complexity of ubiquitin ligation of Smads and receptors is likely to be matched by an array of DUB counterparts. Recently, we have begun attempts to identify novel DUBs bound to Smads and receptors using activity-based HA (haemagglutinin)-tagged ubiquitin probes (Figure 2A , and see [8] ). Preliminary experiments show that these probes are active against UCH37 transiently overexpressed in HEK-293 cells (human embryonic kidney cells) ( Figure 2B ). We are currently in the process of using these probes to identify and [8] for further details). A negative control reaction was performed using 10 µg of UCH37-FLAG lysate but lacking HA-Ub-VME probe. All labelling reactions were performed at 37 • C for 1 h. Lysates and probe reactions were visualized by SDS/PAGE and Western blotting (B), with either anti-FLAG (Sigma) or anti-HA (Roche) primary antibodies, and anti-mouse or anti-rat peroxidase conjugate secondary antibodies respectively (Sigma). As can be seen in the second lane of the right panel in (B), UCH37-FLAG exhibits a shift in molecular mass of approx. 10 kDa due to the combined mass of UCH37-FLAG and HA-Ub-VME probe (band indicated by the star symbol). HA-Ub-VME also appears to have strongly labelled a smaller endogenous protein in HEK-293 cells visualized at the same molecular mass as unlabelled UCH37-FLAG (arrowhead).
characterize the full complement of DUBs specifically bound to Smad and TGF-β receptor immunoprecipitates.
Concluding remarks
We have identified a completely novel regulatory mechanism in the TGF-β pathway involving the DUB UCH37 in complex with Smad7. This represents a novel intracellular mechanism that may function to stabilize or re-activate TGF-β signalling that has been repressed by the Smad7-Smurf complex. Overall, it is likely that the balance between Smurf-mediated ubiquitination and UCH37-mediated deubiquitination is critical for fine-tuning responses. Dysregulation of this important regulatory mechanism could contribute to aberrant TGF-β signalling seen in tumorigenesis, fibrosis and many other human diseases. We predict that targeting the UCH37-Smad7 complex could provide a new approach for treating human diseases in which there is overt up-regulation in TGF-β signalling activity. It is anticipated that the application of activity-based DUB probes and functional proteomic approaches will also identify the full spectrum of DUB activity impacting on TGF-β signalling activity, and provide additional therapeutic targets.
